There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Homology Medicines (FIXX – Research Report), Mereo Biopharma Group Plc (MREO – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments.
Homology Medicines (FIXX)
BTIG analyst Robert Hazlett maintained a Buy rating on Homology Medicines yesterday and set a price target of $12.00. The company’s shares closed last Tuesday at $1.07, close to its 52-week low of $1.04.
According to TipRanks.com, Hazlett is a 2-star analyst with an average return of -0.4% and a 35.0% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Eiger Biopharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Homology Medicines is a Moderate Buy with an average price target of $9.20, which is an 890.8% upside from current levels. In a report issued on March 10, Robert W. Baird also maintained a Buy rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Mereo Biopharma Group Plc (MREO)
In a report released yesterday, Yun Zhong from BTIG maintained a Buy rating on Mereo Biopharma Group Plc, with a price target of $4.00. The company’s shares closed last Tuesday at $0.87.
According to TipRanks.com, Zhong has 0 stars on 0-5 stars ranking scale with an average return of -23.1% and a 25.3% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Taysha Gene Therapies, and Voyager Therapeutics.
Currently, the analyst consensus on Mereo Biopharma Group Plc is a Moderate Buy with an average price target of $4.00.
BridgeBio Pharma (BBIO)
Bank of America Securities analyst Greg Harrison maintained a Buy rating on BridgeBio Pharma yesterday and set a price target of $18.00. The company’s shares closed last Tuesday at $13.46.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of 4.1% and a 45.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $25.86 average price target, which is an 87.0% upside from current levels. In a report issued on March 6, Raymond James also maintained a Buy rating on the stock with a $29.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FIXX: